Migraine is more than a severe headache. It is a neurological condition that can cause throbbing pain, nausea, dizziness, sensitivity to light and sound, and difficulty carrying out everyday activities.
Prescription treatments remain central to migraine care. Researchers are also studying complementary options, including palmitoylethanolamide (PEA), a fatty acid compound made naturally by the body that may influence pain and inflammatory pathways.
Early studies suggest PEA could help some people with migraine symptoms. The evidence is still limited, though, and there are important precautions to consider before adding a supplement to your treatment plan.
What is PEA?
Palmitoylethanolamide, commonly called PEA, is a naturally occurring fatty acid amide. The body produces it and it is also present in small amounts in some foods. Researchers are studying its role in regulating inflammation and pain signaling.
PEA may act on several pathways, including peroxisome proliferator-activated receptor alpha (PPAR-α). It is sometimes described as an endocannabinoid-like compound, but it is not marijuana, THC, or CBD and does not produce a marijuana-like high.
How could PEA help with migraines?
Migraine involves changes in how the nervous system processes pain. Researchers are studying whether PEA’s effects on inflammatory and pain-signaling pathways could ease symptoms. Possible benefits under investigation include:
Less pain during an attack
A 2024 randomized, double-blind, placebo-controlled study tested a specialized PEA formulation called Levagen+. Participants took it when a migraine began. The study found improvements in some pain and headache-resolution measures compared with placebo.
Shorter attacks
In the same study, more migraine events had resolved by two and eight hours in the PEA group. The trial was relatively small and included otherwise healthy adults, so its findings may not apply to everyone with migraine.
Less use of rescue medication
Participants taking PEA used less rescue medication overall during the study. PEA has not been shown to prevent medication-overuse headache. Continue to follow your prescribed acute-treatment plan and discuss frequent medication use with your clinician.
Possible support for prevention
A 2025 randomized trial studied a daily combination of PEA and melatonin for three months. Participants in the combination group had improvements in migraine frequency, duration, intensity, and disability. Because PEA was given with melatonin, the study cannot show how much benefit came from PEA alone. More and larger trials are needed before PEA can be routinely recommended for prevention.
What does the research show?
Two recent clinical trials provide early information, but they do not establish PEA as a standard migraine treatment.
Acute migraine study (2024): The Levagen+ trial evaluated 600 mg at migraine onset, with a second dose allowed after two hours if symptoms persisted. Researchers reported improvements in some pain and headache-resolution measures and lower overall rescue-medication use. No adverse events were reported in either group during the study.
Prevention study (2025): A three-month trial involving 60 participants who completed treatment studied a daily combination of 1,200 mg hydrodispersible PEA and 0.2 mg melatonin. The treatment group improved on several migraine measures. The small sample and combined ingredients limit what can be concluded.
What this means: PEA is a possible complementary option that deserves further study. Current evidence is not strong enough to recommend it as a first-line treatment for an acute attack or for migraine prevention.
How much PEA is used for migraines?
There is no standardized, evidence-based PEA dose for migraine. Clinical studies have tested different formulations and regimens:
Acute migraine research: 600 mg at onset, with another 600 mg after two hours if needed.
Prevention research: 1,200 mg daily combined with 0.2 mg melatonin.
These are research protocols, not universal dosing instructions. Products can differ in formulation and absorption. Talk with your neurology provider before starting PEA, especially if you take other medicines or have a chronic health condition.
PEA safety and precautions
Side effects and long-term safety
PEA appeared to be well tolerated in the small migraine trials described above, which reported few or no adverse events. That does not establish that it is risk-free. Larger and longer studies are needed to identify uncommon side effects and better understand long-term use. Stop taking a supplement and contact your healthcare provider if you develop an unexpected or concerning reaction.
Pregnancy and breastfeeding
There is not enough reliable safety information to recommend routine PEA supplementation during pregnancy or breastfeeding. If you are pregnant, planning pregnancy, or breastfeeding, consult your healthcare provider before using it.
Medication interactions
Comprehensive studies of PEA interactions with prescription medicines are lacking. Review it with your healthcare provider or pharmacist before use, particularly if you take several medicines or have other medical conditions. A lack of documented interactions does not guarantee that every combination is safe.
Supplement quality
PEA products are sold in different formulations, including micronized, ultramicronized, and enhanced-absorption preparations. Products may vary in ingredients, manufacturing quality, and absorption. Look for a manufacturer that provides independent testing for identity, purity, and contaminants. In the United States, the FDA does not approve dietary supplements for safety and effectiveness before they are marketed.
Do not stop prescribed migraine treatment on your own
PEA should not automatically replace prescribed migraine treatments, such as triptans, CGRP-targeting medicines, other preventive therapies, or Botox for appropriate patients with chronic migraine. If your current treatment is helping, do not stop or change it without discussing that decision with your healthcare provider.
Who might discuss PEA with a neurology provider?
You may want to ask about PEA if you have recurring migraine attacks despite treatment, are considering complementary approaches, have difficulty tolerating some medications, or want to review the supplements you take. Whether it fits your care plan depends on your migraine history, medicines, health conditions, and treatment goals.
When should you seek medical attention?
Do not assume every new or severe headache is a migraine. Seek emergency care for a sudden, extremely severe headache; new weakness; trouble speaking; loss of vision; confusion; or other sudden neurological symptoms. A headache with fever and neck stiffness also needs urgent medical evaluation.
The bottom line
Palmitoylethanolamide is being studied for its possible effects on pain and inflammation. Early migraine studies suggest potential benefits for some acute symptoms and for prevention when combined with melatonin, but the evidence remains limited.
For now, PEA is best viewed as a possible complementary option to discuss with a healthcare provider, not a proven replacement for established migraine treatment.
At Neuro On Call, we believe migraine care should be individualized and evidence-based. If migraines are interfering with your daily life, a neurological evaluation can help identify treatment options suited to your needs.
Schedule a virtual neurology appointment
Neuro On Call, PLLC
Convenient virtual neurological care from the comfort of your home.
Website: neurooncall.org
Schedule an appointment
Disclaimer: This article is for educational purposes only and does not replace individualized medical advice. Consult a qualified healthcare professional before starting a new supplement or changing prescribed treatment.
References
Briskey D, et al. Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants. Pharmaceuticals. 2024;17(2):145. doi:10.3390/ph17020145
Piccolo V, et al. Fixed Combination of Palmitoylethanolamide and Melatonin in Preventive Therapy of Migraine: Results From a Randomized Clinical Trial. Frontiers in Nutrition. 2025;12:1560654. doi:10.3389/fnut.2025.1560654
Bortoletto R, et al. Palmitoylethanolamide Supplementation for Human Health: A State-of-the-Art Systematic Review of Randomized Controlled Trials in Patient Populations. Brain, Behavior, & Immunity - Health. 2025;43:100927. doi:10.1016/j.bbih.2024.100927
U.S. Food and Drug Administration. Information for Consumers on Using Dietary Supplements.
